Alkermes plc (8AK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Alkermes plc (8AK) has a cash flow conversion efficiency ratio of -0.095x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-165.74 Million ≈ $-193.77 Million USD) by net assets (€1.75 Billion ≈ $2.05 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 8AK equity financing ratio to measure how much of total assets are equity-financed.
Alkermes plc - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Alkermes plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 8AK cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Alkermes plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alkermes plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Impack Pratama Industri Tbk
JK:IMPC
|
0.068x |
|
Bharat Dynamics Limited
NSE:BDL
|
-0.019x |
|
Sinomine Resource Exploration Co Ltd
SHE:002738
|
0.070x |
|
Rigetti Computing Inc
NASDAQ:RGTI
|
-0.028x |
|
Colliers International Group Inc Bats
TO:CIGI
|
-0.068x |
|
Scout24 AG
XETRA:G24
|
0.101x |
|
Clal Insurance Enterprises Holdings Ltd
TA:CLIS
|
0.136x |
|
Construction Partners Inc
NASDAQ:ROAD
|
0.067x |
Annual Cash Flow Conversion Efficiency for Alkermes plc (2013–2025)
The table below shows the annual cash flow conversion efficiency of Alkermes plc from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Alkermes plc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €1.82 Billion ≈ $2.13 Billion |
€520.75 Million ≈ $608.82 Million |
0.286x | -4.51% |
| 2024-12-31 | €1.46 Billion ≈ $1.71 Billion |
€439.12 Million ≈ $513.38 Million |
0.300x | -10.18% |
| 2023-12-31 | €1.20 Billion ≈ $1.41 Billion |
€401.35 Million ≈ $469.22 Million |
0.334x | +1555.17% |
| 2022-12-31 | €1.04 Billion ≈ $1.22 Billion |
€21.04 Million ≈ $24.60 Million |
0.020x | -77.95% |
| 2021-12-31 | €1.11 Billion ≈ $1.30 Billion |
€101.72 Million ≈ $118.92 Million |
0.091x | +7.86% |
| 2018-12-31 | €1.17 Billion ≈ $1.37 Billion |
€99.28 Million ≈ $116.07 Million |
0.085x | +431.28% |
| 2017-12-31 | €1.20 Billion ≈ $1.41 Billion |
€19.19 Million ≈ $22.44 Million |
0.016x | +130.24% |
| 2016-12-31 | €1.21 Billion ≈ $1.41 Billion |
€-63.80 Million ≈ $-74.59 Million |
-0.053x | -71.78% |
| 2015-12-31 | €1.31 Billion ≈ $1.54 Billion |
€-40.36 Million ≈ $-47.19 Million |
-0.031x | -485.09% |
| 2014-12-31 | €1.40 Billion ≈ $1.63 Billion |
€11.14 Million ≈ $13.02 Million |
0.008x | -94.24% |
| 2013-12-31 | €1.07 Billion ≈ $1.25 Billion |
€147.53 Million ≈ $172.47 Million |
0.138x | -- |
About Alkermes plc
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and … Read more